Elevise Diabetes Care announces Strategic Alliance with Insulet Corporation to connect the BGMS Contour®next One and the PDM Omnipod Dash ™.
Eleviseia Diabetes Care announced today that he has celebrated a strategic alliance through the signing of a development agreement with Insulet Corporation (Nasdaq: Podd), leader in insulin pump technology without tube with its Insulin administration system Omnipod® (the OMNIPOD system).
According to the terms of this agreement, the blood glucose control system (Blood Glucose Monitoring System, BGMS) Contour®next One of Ascensia will connect with the OMNIPOD (the OMNIPOD DASH ™ System) next generation of INSUET, which currently currentlyIt is in development.The perfect connection of the BGMS Contour®Next One and the OMNIPOD DASH ™ system will provide those who suffer from diabetes from an innovative continuous insulin administration system, with extremely precise blood glucose readings.
Through low -energy Bluetooth (Bluetooth low energy, BLE), BGMS Contour®Next One will work with the Personal Diabetes Dash ™ diabetes administrator (PDM Omnipod Dash ™) to automatically transmit blood glucose readings of a patient directly to the system.These readings will be used by the PDM Omnipod Dash ™ to calculate the dose of insulin and enable an extremely precise insulin administration for people suffering from diabetes.In accordance with the terms of the non -exclusive World Agreement, Insulet will develop and seek authorization to market PDM Omnipod Dash ™, with the collaboration of Eleviseia Diabetes Care who will provide the Contour®next One meter and the Contaur®Next test strips.
"We are very happy to hold this agreement that brings together these two innovative technologies of both companies," said Michael Kloss, CEO of Eleviseia Diabetes Care."The integration of our BGM system with the Insulin pump system without an insulet tube has an important potential to help people control their lives and diabetes. We are pleased that our very precise system has been chosen to provide critical data onBlood glucose that will be used by PDM Omnipod Dash ™ to calculate the insulin dose for patients. "
"We are excited to associate with elevation as part of our development tasks on our next -generation Omnipod Dash platform, which will allow Insulet to maintain its competitive advantage with truly innovative and differentiated products," said Shacey Petrovic, president and general director of Operations.
The BGMS Contour®next One received approval 510 (K) of the FDA in November 2016 and has proven to meet the most strict precision demands of the FDA guideline for free sale bgms recently published in 2016. In a studyClinical, 95% of blood glucose results obtained with BGMS Contour®next One were within 8.4 mg/dl (0.5 mmol/l) or 8.4% of the reference values for tests for tests ofPatient fingers yolks [1].
Michael added: "This alliance is the next step in our goal of providing integrated solutions for people suffering from diabetes. We believe that an integrated diabetes treatment is the future and we are glad to work with partners that will help us achieve this goal inSet.of omnipod product ".
About Elevise Diabetes Care
Elevise Diabetes Care is a global company specialized in the treatment of diabetes and dedicated to helping those who suffer from diabetes.Our mission is to empower those whoThey suffer from diabetes through innovative solutions that simplify and improve their lives.We use our innovation and our experience as diabetes specialists to develop high quality solutions and tools that set a positive daily difference for people who have diabetes.
Hogar of the world -known portfolio of blood glucose monitoring systems, our products combine advanced technology with simple use functionality that helps people with diabetes handle their disease.We have the commitment to continue with the research, innovation and development of new products and solutions.As a trusted partner in the Diabetes Community, we collaborate closely with health care professionals and other associates to ensure that our products comply with the highest standards of accuracy, precision and reliability, and that our businesses are carried out with integrityand in compliance with the rules.
Elevise Diabetes Care was created in 2016 through the sale of Bayer Diabetes Care to Panasonic Healthcare Holdings Co., Ltd. The Products of Evenia Diabetes Care are sold in more than 125 countries.Elevise Diabetes Care has approximately 1,700 employees and operations in 33 countries.
If you want more information, please visit the Eleviseia Diabetes Care website at: Link
About Insulet Corporation
Insulet Corporation (Nasdaq: Podd) is an innovative medical devices dedicated to improving the lives of people suffering from diabetes.Through its Omnipod insulin administration system, Insulet seeks to expand the use of insulin pump therapy among insulin -dependent diabetics.Omnipod is an insulin pump without a tube, revolutionary and easy to use, which provides up to three days of continuous insulin administration, without the need to control or handle a needle.The Business Unit Insulet Administration Systems is also associated with global pharmacy and biotechnology companies to adapt the Omnipod technology platform for the administration of subcutaneous drugs in multiple therapeutic areas.Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts.If you want more information, follow visit: Link
© 2017 Elevise Diabetes Care.Elevise and Contour are trademarks and/or registered trademarks of Even Diabetes Care.All other trademarks are owned by their respective owners.The use of third -party trademarks does not constitute support or imply a relationship or other link.
